Iovance Biotherapeutics (IOVA) Assets Average (2011 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Assets Average of $919.4 million for Q1 2026, down 2.04% year-over-year from $938.6 million in Q1 2025, and up 1.14% quarter-over-quarter from $909.1 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Assets Average (2011 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Assets Average for 15 consecutive years, with $919.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 2.04% year-over-year to $919.4 million; the TTM figure through Mar 2026 stood at $919.4 million (down 2.04% YoY), while the FY2025 annual figure was $911.8 million, up 7.86% from the prior year.
- Assets Average climbed to $919.4 million in Q1 2026 per IOVA's latest filing, from $909.1 million in the prior quarter.
- Across five years, Assets Average topped out at $938.6 million in Q1 2025 and bottomed at $578.4 million in Q3 2022.
- Historically, Assets Average has averaged $797.9 million across 5 years, with a median of $810.6 million in 2023.
- Annual changes were most pronounced in 2022 — Assets Average plunged 31.21% — and 2023, when it jumped 39.14%.
- Iovance Biotherapeutics' Assets Average stood at $605.0 million in 2022, then jumped by 34.94% to $816.3 million in 2023, then gained by 1.07% to $825.1 million in 2024, then advanced by 10.18% to $909.1 million in 2025, then grew by 1.14% to $919.4 million in 2026.
- Business Quant data shows IOVA's Assets Average at $919.4 million in Q1 2026, $909.1 million in Q4 2025, and $906.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 920.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 920.60 Mn |
| Mar 31, 2026 | 919.42 Mn |
| Dec 31, 2025 | 909.06 Mn |
| Sep 30, 2025 | 906.19 Mn |
| Jun 30, 2025 | 937.09 Mn |
| Mar 31, 2025 | 938.58 Mn |
| Mar 31, 2024 | 825.09 Mn |
| Dec 31, 2023 | 816.33 Mn |
| Sep 30, 2023 | 804.80 Mn |
| Jun 30, 2023 | 791.03 Mn |
| Mar 31, 2023 | 744.37 Mn |
| Dec 31, 2022 | 604.95 Mn |
| Sep 30, 2022 | 578.40 Mn |
| Jun 30, 2022 | 656.06 Mn |
| Mar 31, 2022 | 739.29 Mn |
| Dec 31, 2021 | 803.08 Mn |
| Sep 30, 2021 | 840.81 Mn |
| Jun 30, 2021 | 801.68 Mn |
| Mar 31, 2021 | 759.52 Mn |
| Dec 31, 2020 | 775.38 Mn |